Breaking News: Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test

Breakout Alert: Wednesday February 22, 2023 [NOTICE] Premium Alert (NASDAQ: MYNZ) Just Triggered a Total of 21 "[Strong Buy]( Surge Coming? Hi 10XProTrader Member, I have a really important message to get in front of you right now regarding my latest premium stock alert which is Mainz Biomed N.V. (Nasdaq: MYNZ). MYNZ Triggered 21 "[Strong Buy]( On The Moving Averages & Technical Indicators Are you watching MYNZ right now? If that was a No, I suggest that you pay close attention starting right now. - (MYNZ) just Triggered "12" Strong Buys in the Moving averages - (MYNZ) just Triggered "9" Strong Buys in the Technical Indicators Additionally, MYNZ is looking extremely bullish right now. The volume was 5X greater yesterday than usual as well. Can we see MYNZ surge to $8, $9, $11+ Image by Investing.com via Breaking News Hits Wire MYNZ Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program Breaking news hit the wire yesterday regarding our new premium alert MYNZ. Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program. This could be the exact catalyst sparks shareholder momentum in MYNZ! View News Source [Here:]( Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe. Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. (“SOCPRA”), to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression (mRNA) biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease. “This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the oppor∙tunity to ramp-up corporate development activities,” added Baechler. Mainz Biomed is commercializing ColoAlert across Europe and in select international markets through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. Under the standard terms of all partnerships, Mainz Biomed is providing ColoAlert to the respective labs, including co-branding with key accounts, whereby each facility purchases Mainz Biomed’s customized polymerase chain reaction (“PCR”) assay kits on an on-demand basis and provides their respective network of physicians and patients with a comprehensive solution for advanced CRC detection. The Company is in the process of evaluating the mRNA biomarkers it is has acquired from SOCPRA in ColoFuture and eAArly DETECT, an international multi-center clinical study (US and Europe) assessing the potential for the integration of the mRNA biomarkers into ColoAlert. This particular portfolio of mRNA biomarkers selected by Mainz Biomed was based on work in the field by the University of Sherbrooke, where researchers tested multiple novel transcriptional biomarkers using colorectal cancer and precancerous lesion samples. The results from these studies demonstrated that the mRNA targets chosen by the Company provided a dynamic combination of sensitivity and specificity of detection (Herring et al. 2021). The ColoFuture study (extended into the US as eAArly DETECT) is evaluating the effectiveness of these biomarkers to enhance ColoAlert’s technical profile to expand its capability to identify AA while increasing ColoAlert’s rates of diagnostic sensitivity and specificity. ColoFuture’s eAArly DETECT study is on track to complete enrollment in the first quarter of 2023, with results reported in the first half of 2023. Based on the study’s outcome, Mainz Biomed will decide on integrating the biomarkers into the ReconAAsense study, which is on track to enroll patients in the summer of 2023, with results reported in 2025. The ReconAAsense study (ClinicalTrials.gov Identifier: NCT05636085) will form the basis of the data package for review by the US Food and Drug Administration (FDA) to achieve marketing authorization. It is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States. The study objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA. If successful, the Company’s mRNA and DNA-based CRC screening test will be positioned as the most robust and accurate at-home diagnostic screening test on the market, as it will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas. About ColoAlert ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy (Dollinger MM et al., 2018). The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT). It is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVDR marked (complying with EU safety, health and environmental requirements) and commercially available in a selection of countries in the European Union and the United Arab Emirates. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. If approved in the United States, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country. About Colorectal Cancer According to the Centers for Disease Control and Prevention (“CDC”), CRC is the second most lethal cancer in the United States and Europe, but also the most preventable, with early detection providing survival rates above 90%. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the US, with 52,980 resulting in death. Recent decisions by the U.S. Food and Drug Administration (FDA) suggest that screening with stool DNA tests such as ColoAlert in the United States should be conducted once every three years starting at age 45. Currently, there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years and a US market oppor∙tunity of approximately $3.7 billion per year. About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for CRC. ColoAlert is currently marketed across Europe and in select international territories. The Company is currently running a pivotal FDA clinical study for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook. FDA Approval Could Send This Tiny Biotech Soaring Mainz Biomed N.V. (NASDAQ: MYNZ) The Company has several bullish catalysts in the pipeline and is on the verge of Disrupting the multi-billion-do∙ll∙ar colorectal cancer diagnostics space with their latest blockbuster News. Multiple Analysts Bullish on MYNZ, following latest updates and Blockbuster News. Bullish Catalyst - H.C. Wainwright Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with a Buy rating and $25 Price Target [ (Representing 259% in Upside Potential) ]( Initiating with Buy Rating and $25 PT The price target at $25 implies over 259% upside to Friday Feb 17th, closing price and stands higher than the current $18.00 average price target for MYNZ on Wall Street. Symbol: MYNZ Company Name: Mainz Biomed N.V. Breakout Catalyst: (+++) Analysts $25.00 PT, $15 PT, $11 PT Analyst Coverage: H.C. Wainwright, Cantor Fitzgerald, Jones Research About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomeds product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. Mainz BioMed Aims to Become a Leader in The Multi-Billion Do∙ll∙ar Colorectal Cancer Diagnostics Market! - ColoAlert holds potential as a Blockbuster Early Detection Test for Colorectal Cancer. - Designed for pro∙fita∙bility, rapid commercial uptake, and broad consumer acceptance. - Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. - Mainz BioMed is developing proprietary genetic testing methods for pancreatic cancer. Mainz Biomed is a diagnostics biotech company with near-term catalysts, small float, potential chart breakout, coming off of great news and recent multiple analysts coverage indicating 58%,115%, 259% in upside potential. MYNZ CE-IVD Cleared Flagship Product ColoAlert is the FIRST DNA-based Screening Test for Colorectal Cancer in Europe Note* Mainz Biomed ColoAlert test is currently approved and commercially available in Europe and select International markets. Sales, commercial partnerships and marketing activities are starting to ramp up now! This leaves an open door for multiple near-term catalysts. MYNZ Enters Commercial Partnerships for ColoAlert with Two Independent Laboratories News Announced Feb. 15, 2023 - Mainz Biomed (Nasdaq: MYNZ) has formed commercial partnerships for ColoAlert with Marylebone Laboratory and Instituto de Microecologia, two leading independent laboratories covering England and Spain. Mainz Biomed markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe and being commercialized in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. In the forthcoming weeks, Mainz Biomed will work with both partners to complete the necessary technical and co-marketing activities to ensure a successful commercial launch in these markets. Bullish Catalyst - Cantor Fitzgerald Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with an OW Rating and $15 Price Target. [ (Representing 115% in Upside Potential) ]( Initiating with Buy Rating and $15 PT The price target at $15 implies over 115% upside to Friday Feb 17th, closing price but stands lower than the current$18 average price target for MYNZ on Wall Street. Mainz Biomed Draws Bullish Views at Cantor Fitzgerald on Potential in Colorectal Cancer Screening Cantor Fitzgerald initiated its coverage on Cancer diagnostics test maker Mainz Biomed B.V. (Nasdaq: MYNZ) with an Overweight recommendation noting the company’s prospects in colorectal cancer screening. Mainz Biomed markets ColoAlert non-invasive test for colorectal cancer (CRC) screenings in Europe, and its “European sales provide near-term revenue potential while the company prepares to enter the U.S. market,” the analyst Ross Osborn argues. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13BIL, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert. Commenting on Mainz Biomed’s valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” Bullish Catalyst - Jones Research Initiated Coverage of Mainz Biomed (Nasdaq: MYNZ) with an Buy Rating and $11 Price Target. [ (Representing 58% in Upside Potential) ]( Initiating with Buy Rating and $11 PT The price target at $11 implies 58% upside to Friday Feb 17th, closing price but stands lower than the current $18 average price target for MYNZ on Wall Street. Jones Research Initiated Feb. 9th, 2023 - Staking Its Claim In The Booming CRC Screening Market Jones Research Report Highlights: "The future one sample – multiple screenings. In addition to efforts to improve early detection by incorporating mRNA biomarkers into ColoAlert, Mainz is developing PancAlert. PancAlert is a stool-based early detection screening test for pancreatic cancer. While the company is still evaluating the sensitivity of the product and it remains in the early research stage, we are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz Biomed, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." "Key Catalyst: mRNA feasibility study readout (1H23); 2) begin enrollment in pivotal ReconAAsense trial (mid-2023)." "Valuation: Their $11 price target is based on risk-adjusted discounted cash flow (DCF) valuation with cash flows forecasted through 2034, along with a 12.5% discount rate and a 0% terminal growth rate. We assume a probability of success of 90% for ColoAlert in the U.S." Mainz Biomed (Nasdaq: MYNZ) Targets Multi-Billion-Do∙ll∙ar Sales Oppor∙tunity With Best-In-Class Cancer Screening Diagnostics Mainz Biomed is showing bullish momentum following several milestones reached, including strengthening its board and medical advisory team and expanding its best-in-class cancer diagnostics products deeper into international markets. Mainz Biomed (MYNZ) Has Demonstrated the Ability to Run Up Fast! While the recent bullish action is impressive, it's likely the potential precursor of more significant moves to come. Multiple Analysts on Wall Street released target price's on Mainz Biomed which I listed above. Mainz Biomed is currently hovering around approx. $7.00/share. If you're looking for a potential double or even a triple-digit-breakout, analysts predict this is the stock to do that. Now Turn Your Complete Attention to Mainz Biomed (Nasdaq: MYNZ) Our New Premium Nasdaq Biotech Breakout Alert for Tuesday! Take a look at the Chart below, you will see roughly around this same time last year, MYNZ ran from approx. $7.00/share range to a high of $30.00. Back in January of 2022, I started tracking this company, and I began to see very clear breakout patterns happening over and over in short-term burst scenarios. I initiated coverage of MYNZ for the first time at the closing bell on January 4th, 2022, when the stock was trading at approx. $10/share. ...10 short-days later, MYNZ rocketed to a staggering high of $30.00/share. Around This Same Time Last Year MYNZ Rocketed From The Same Range of approx. $7.00/share to a High of $30.00! See Chart Image by Scanz Level II via Immediately turn your attention to Mainz Biomed (Nasdaq: MYNZ) or you could miss out on the next potential 200% Biotech Breakout Stock! MYNZ Could See Some Action Early Tuesday Morning! Just like the first time I initiated coverage on MYNZ, the stock could be in the beginning stages of a potential breakout to the upside… The first time I alerted MYNZ it went from $10.00 to a staggering high of $30.00 for a 200% gain in 10 days… You will want to hurry and pull MYNZ up as soon as possible. Mainz Biomed is setting up to be a key player in the extremely Booming Billion-Do∙ll∙ar Biotech sector focusing on “early detection of cancer” using its Blockbuster Early Detection Test for Colorectal Cancer! MYNZ Has “10” Key Potential Breakout Catalysts That Provide A Very Bullish Outlook - Catalyst #1: Multiple Analysts Bullish on MYNZ, following latest updates and Blockbuster News. See below - Catalyst #2: H.C. Wainwright Initiated Coverage of MYNZ with a Buy rating and $25 Price Target. The price target at $25 implies over 259% upside to Friday Feb 17th, closing price and stands higher than the current $18.00 average price target for MYNZ on Wall Street. - Catalyst #3: Cantor Fitzgerald Initiated Coverage of MYNZ with an OW Rating and $15 Price Target. The price target at $15 implies over 115% upside to Friday Feb 17th, closing price but stands lower than the current $18 average price target for MYNZ on Wall Street. The analyst issues positive views on the E.U. and U.S. CRC screening market, estimated at $13BIL, and notes that the company’s partnership model is likely to improve the adoption of ColoAlert. Commenting on Mainz Biomed's valuation disparity with Exact Sciences Corporation (EXAS), its U.S.-based rival in colorectal screening, Osborn argues that the company can close the valuation gap as its sales “volumes accelerate and ColoAlert receives FDA approval.” - Catalyst #4: Jones Research Initiated Coverage of MYNZ with an Buy Rating and $11 Price Target. The price target at $11 implies 58% upside to Friday Feb 17th, closing price but stands lower than the current $18 average price target for MYNZ on Wall Street. We are intrigued by the possibilities of screening for multiple cancers using the same stool-sample (i.e., making use of both ColoAlert and PancAlert). Not only could this offer considerable synergies for Mainz, but it could also improve patient outcomes with no increased inconvenience. Theoretically, the company could expand beyond CRC and pancreatic cancer from there and provide early detection of multiple cancers that are amenable to stool-based screening. While we wait for clinical validation of PancAlert, however, we are not including future revenues in our model and leave the product as a source of potential upside for investors." - Catalyst #5: Mainz Biomed states that they will be seeking to obtain FDA approval for ColoAlert. The company just appointed Karen Richards as Vice President, Regulatory Affairs to lead the company through the FDA Approval Process. According to a recent press release from Mainz Biomed, the company CEO stated that Karen Richards brings specific expertise in shepherding diagnostic products through the U.S. regulatory process. ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. If Mainz Biomed gets FDA Approval for ColoAlert, who knows what could happen to the share price of Mainz. FDA Approval could potentially send the share price of MYNZ soaring. - Catalyst #6: Mainz Biomed is in the same space as Exact Sciences Corporation (EXAS) and over the last 5 years, their stock price has ran as much as +736.84% and currently has a market cap of over $11BIL which is around approx. 130x times the size of MYNZ. If Mainz Biomed could potentially grow its market cap equal to the current size of Exact Sciences Corporation (EXAS), that could mean a share price appreciate from around $10.39 to over $1,350 or the equivalent of a +12,893.26% potential gain. A move like that would be like turning $5,000 into over $600,000. - Catalyst #7: Mainz Biomed could potentially become the acquisition target of a much larger player in the space. Within the last year there have been multiple noteworthy acquisitions like Roche to acquire GenMark Diagnostics for $1.8BIL, DiaSorin to buy Luminex for $1.8BIL, Quidel Corporation (Nasdaq: QDEL) acquire Ortho Clinical Diagnostics (Nasdaq: OCDX) for $6BIL. There seems to be some deal making heating up in this space and if a larger player shows interest in (Nasdaq: MYNZ), there is no telling what could potentially happen to the share price. - Catalyst #8: Mainz Biomed (MYNZ) is listed on the NASDAQ exchange which allows pre-market trading. If there is any significant pre-market activity before the opening bell on Tuesday morning, things could heat up very fast when buying attracts more buying as investors and traders look to position themselves ahead of the crowd. You need to have MYNZ pulled up on your screen and ready for some action if this thing looks like it's ready to break out to the upside. - Catalyst #9: Mainz Biomed is led by a very seasoned and experienced Management Team. The company's CEO, Guido Baechler has over 30 years of global experience leading public & private life science companies. Its CFO, William Caragol, has over 30 years of experience working with growth stage technology companies and is the Ex-Board Chair of Thermomedics, Inc., a privately held medical diagnostic equipment company. Karen Richards was recently appointed as Vice President of Regulatory Affairs, responsible for driving the development of new IVD products in compliance with regulatory requirements which is particularly important as she brings specific expertise in shepherding diagnostic products through the U.S. regulatory process, including the FDA. - Catalyst #10: The Company made key appointments to the management team and enhanced its Board of Directors and Medical Advisory Board: Darin Leigh, Chief Commercial Officer – Mr. Leigh is a former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science experience. Amy Levin, Vice President of Regulatory Affairs – Ms. Levin brings to Mainz Biomed over 20 years of regulatory affairs experience. Previously, she worked as Director, Roche Molecular Diagnostics (RMD) International Regulatory Affairs. Jane Edwards, Vice President of Clinical Affairs – Ms. Edwards, has over 20 years of experience developing clinical trial strategies in diagnostics and medical devices. She was previously at L3 Healthcare, a full-service contract research organization, where she led clinical research and operations. Frank Krieg-Schneider, Vice President of Development – Mr. Krieg has over 25 years of experience in the diagnostics and life science industry, including leading various divisions within Qiagen’s diagnostic and life science practice, heading up research and development for Diagnostic Sample Preparation and later serving as Head of Global Strategic Alliances. Final Thoughts… Note* MYNZ is listed on the NASDAQ and has the ability to trade in after market trading hours and pre-market! Remember, any significant pre-market activity could potentially trigger a bu∙y∙ing frenzy at the opening bell! The first time I alerted MYNZ it went from $10/share to a staggering high of $30/share for a 200% gain. For those of you who missed MYNZ the first time I alerted it, when it went from $10.00 to a staggering high of $30.00. I would hate to see you miss out again. If you haven't taken a look at this stock yet, this is your chance. Make sure you have MYNZ pulled up on your trading screen. 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: 1): 2): 3): 4): 5): 6): 7): 8): Leg∙al Entity Information: 10XProTrader is a website owned and operated by 10XPublishing, LLC., which is a DBA of 10XMedia, LLC. You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Help line: Customer service number is 1-800-803-4811 Mailing Address: Attn: Member Services | 10XMedia, LLC. 340 Royal Poinciana Way Suite 317-#409 Palm Beach, FL 33480 Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XMedia, LLC. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is a paid advertisement. 10XProTrader.coms is owned and operated by 10XMedia LLC, which is a Florida based Limited Liability Company and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please review the full disc∙laimer at [( for important information about this advertisement. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.